NASDAQ · KLRS
Healthcare · Biotechnology
$3.18
Down-$0.02 (-0.62%)
Updated Sep 17, 2026, 7:13 AM
SID Score
2.7/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
KLRS closed at $3.18 after 20 trading sessions, down 23.74% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 16, 2026 | $3.1501 | $3.25 | $3.10 | $3.18 | 61.75K |
| Sep 15, 2026 | $3.35 | $3.355 | $3.20 | $3.20 | 109.36K |
| Sep 14, 2026 | $3.41 | $3.445 | $3.25 | $3.30 | 57.63K |
| Sep 11, 2026 | $3.39 | $3.44 | $3.27 | $3.38 | 95.1K |
| Sep 10, 2026 | $3.55 | $3.66 | $3.30 | $3.30 | 60.82K |
| Sep 9, 2026 | $3.66 | $3.68 | $3.45 | $3.47 | 82.98K |
| Sep 8, 2026 | $3.88 | $3.90 | $3.60 | $3.63 | 100.72K |
| Sep 4, 2026 | $3.91 | $3.95 | $3.82 | $3.90 | 23.86K |
| Sep 3, 2026 | $3.97 | $4.0399 | $3.905 | $3.94 | 39.99K |
| Sep 2, 2026 | $3.97 | $4.135 | $3.90 | $3.90 | 17.27K |
| Sep 1, 2026 | $3.96 | $4.00 | $3.86 | $3.92 | 62.33K |
| Aug 31, 2026 | $3.99 | $4.04 | $3.83 | $4.04 | 19.59K |
| Aug 28, 2026 | $4.12 | $4.15 | $3.89 | $4.03 | 52.61K |
| Aug 27, 2026 | $4.08 | $4.19 | $4.00 | $4.10 | 104.89K |
| Aug 26, 2026 | $4.24 | $4.31 | $3.99 | $4.08 | 28.25K |
| Aug 25, 2026 | $4.04 | $4.25 | $4.04 | $4.20 | 26.26K |
| Aug 24, 2026 | $4.13 | $4.19 | $3.94 | $4.10 | 51.39K |
| Aug 21, 2026 | $4.10 | $4.305 | $3.99 | $4.15 | 81.24K |
| Aug 20, 2026 | $4.20 | $4.20 | $3.97 | $4.12 | 50.21K |
| Aug 19, 2026 | $4.10 | $4.33 | $3.98 | $4.17 | 79.55K |
The latest Smart Investors Daily articles mentioning KLRS.
KLRS research
Company profile and research snapshot.
Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor (VEGF) drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jun 15, 2026 | TD Cowen | Buy | — |
| May 14, 2026 | Wedbush | Outperform | — |
| May 13, 2026 | Citizens | Market Outperform | — |
| Apr 16, 2026 | Morgan Stanley | Overweight | — |
| Dec 23, 2025 | Chardan Capital | Buy | — |
No generated briefing is available yet.
Benzinga · May 12, 2026
Kalaris Therapeutics (NASDAQ:KLRS) reported quarterly losses of $(0.46) per share which beat the analyst consensus estimate of $(0.53) by 13.21 percent. This is a 81.75 percent increase over losses of $(2.52) per share
Finnhub · May 12, 2026
Patient screening now underway in the Phase 1b/2 study with the latest drug product batch on track to be available to support upcoming dosing; preliminary data anticipated in 1H 2027 Planned Phase 3...
newsfilecorp.com · Nov 24, 2025
Berkeley Heights, New Jersey--(Newsfile Corp. - November 24, 2025) - Kalaris Therapeutics, Inc. (Nasdaq: KLRS) ("Kalaris"), a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases, today announced that management will present at the upcoming Noble Capital Markets 21st Annual Emerging Growth Equity Conference. Details: Type: Company presentation Speakers: Matthew Feinsod, Chief Medical Officer Date: Wednesday, December 3, 2025 Time: 11:30 - 11:55 am ET Location: Florida Atlantic University, Boca Raton, FL Kalaris management will be available for one-on-one meetings during the conference.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning KLRS.
